Krystal’s mission is to develop and deliver genetic medicines to patients using redosable gene therapies for the treatment of severe, life‑threatening or rare diseases that have limited or no approved therapies.
Krystal’s first commercial product, VYJUVEK®, is the first and only redosable gene therapy for the treatment of dystrophic epidermolysis bullosa.
With an extensive and promising pipeline, Krystal is advancing an integrated pipeline of genetic therapies to correct the root cause of serious and rare diseases.
Find out about Krystal’s latest announcements, event information, Scientific Publications and our current corporate presentation.
Using a clinically-proven platform, Krystal’s approach is based on a modified and engineered HSV‑1 vector that is replication‑defective and non‑integrating.
With two GMP facilities, find out about what goes into the manufacturing of gene therapies and making transformative medicines.
Krystal is pursuing some of the world’s most debilitating genetic diseases for patients who have limited or inadequate treatment options.
Join the Team
Explore the exceptional career opportunities at Krystal where we are united by a shared purpose and driven to make a difference.
Discovering, developing, and commercializing genetic medicines with purpose